08613920 is referenced by 2 patents and cites 547 patents.

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.

Title
Treatment of amyloidogenic diseases
Application Number
12/297636
Publication Number
8613920 (B2)
Application Date
July 27, 2007
Publication Date
December 24, 2013
Inventor
Michael Grundman
San Diego
CA, US
James Callaway
San Diego
CA, US
Ivan Lieberburg
Berkeley
CA, US
Agent
Alston & Bird
Assignee
Wyeth
NJ, US
Janssen Alzheimer Immunotherapy
IE
IPC
A61P 5/44
A61P 9/12
A61K 49/06
A61K 39/395
View Original Source